All News

mind-the-gap-1876790_640.jpg

#WomenInRheumatology: Is There a Speaker Gender Gap at ACR Meetings?

d Kanika Monga, MD

Recent studies have quantified the gender gap among speakers at academic conferences. The largest study of 181 medical conferences held in North America over one decade found an increase in the proportion of female speakers from 25 to 34% over time, and that the underrepresentation of women was more marked at surgical compared to medical conferences.

Read Article
xray%20spine%20films_0.jpg

IL-17 Inhibitors In Non-Radiographic Axial SpA

d Philip Robinson, MBChB, PhD, FRACP

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

Read Article
hospital-834152_640.jpg

Rheumatic Immune-Related Adverse Events: Not Just Another IrAE

d David Liew, FRACP

Rheumatic immune-related adverse events can start at almost any time after the commencement after immune checkpoint inhibitor immunotherapy for cancer, and are liable to persist long after the immunotherapy has ceased, according to data presented at ACR 2019 in Atlanta, Georgia.

Read Article
Guselkumab, anti-IL23 in PsA Ph3 DISCOVER-1 trial in bio-naive or 30% prior TNFi = Effective at Wk 24 Safety same as with psoriasis trials. No Tb signal, No IBD signal. #ACR19 Abst0807 @_connectedcare https://t.co/d7hrn8VQO8

Links:

Dr. John Cush RheumNow ( View Tweet)

Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/45Vahy36g7 #ACR19 @uptoTate abs#2881

Links:

Dr. John Cush RheumNow ( View Tweet)

I didn’t realize how fast Pegloticase works. Assuming the urate burden of a gout patient, Pegloticase can degrade all the urate in the body over 5-40 days! #ACR19 3S050 Lipsky @_connectedcare

Dr. John Cush RheumNow ( View Tweet)

Panel Presentation: What’s New in Psoriatic Arthritis. So honored to join my colleagues Alexis Ogdie, Jose Scher, and Jessie Walsh to discuss the latest therapies in PsA https://t.co/Hl5r5xVygK via @YouTube #Rheumnow #ACR2019 #ACR19 #PsA

Links:

Eric Ruderman JointMD ( View Tweet)

Crossreactivity events between allopurinol rashes and febuxostat are very low https://t.co/jVVQhtB0CK

Links:

Dr. John Cush RheumNow ( View Tweet)

New package labeling says febuxostat should only be considered after allopurinol has been tried or is contraindicated. https://t.co/Sk2MhEiOhv

Links:

Dr. John Cush RheumNow ( View Tweet)

PANLAR KOL recommendations for MSUS in gout clinic. Abs #301 https://t.co/uziDzNM0VX #ACR19 @uptoTate @RheumNow

Links:

Dr. John Cush RheumNow ( View Tweet)

Great piece by @jeffsparks and team on the role of airway inflammation and the pathogenesis of RA. #rheumatoidarthritis #rheum https://t.co/E2euIPuRab

Links:

John M. Davis, III JohnDavisIII ( View Tweet)

Abstr# 1161: Gadolinium-enhanced MRI of the shoulders showing inflammatory changes in pts with PMR. Helpful to diagnose and detect recurrence. #ACR19 #ACRBest @RheumNow https://t.co/FMvLYtIr3P
Dr. Paul Sufka psufka ( View Tweet)
Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activation syndrome. Highly effective showing ability to lower steroid use #ACR19 #ACRBest https://t.co/OXTwpkyhlq
Dr. John Cush RheumNow ( View Tweet)
All the NEW Clinical Practice Guidelines for GOUT! 1. Allopurinol is 1st line 2. Start ULT during flare! 3. No tx for asymptomatic hyperuricemia Seems pretty reasonable - surprised no rec for MTX w/ pegloticase #ACR19 @EBRheum Thank you to @philipcrobinson for posting slides! https://t.co/jWFa8KnWqM
Dr. John Cush RheumNow ( View Tweet)
#ACR19 ABST #1590 -3 RCTs show anti-TNFα & IL-12/23 associated w/significant improvement in depressive symptoms in PSA. GO-REVEAL depression ⬇️ 31.2 to 19.5% w/golimumab; PSUMIT1 36.2 to 20.3% & PSUMIT2 37.2 to 21.2% ⬇️ w/UST. minimal change w/PBO in all 3 trials @DrPetryna

Dr. John Cush RheumNow ( View Tweet)

NEW Guidelines for the Management of GCA from #ACR19 in one table 1. Recommend Temp Art. Bx over TA U/S for dx GCA 2. Pts should receive TCZ up front 3. Don't treat asymptomatic CRP, monitor patients closely Overall in line with my practice, though I'm pro TA U/S @EBRheum https://t.co/gP3Ta8wD1E
Dr. John Cush RheumNow ( View Tweet)
#ACR19 ABST #1513 Tofacitinib efficacy in PSA ⬇️ if BL BMI ≥ 35 . Safety consistent across all BL BMI categories. 3 CV events: non-fatal cerebrovascular accident, TIA(both Tofa 5 mg BID, BMI ≥ 30 – < 35), and artery revascularization in PBO; BMI ≥ 35 https://t.co/S1WQDRFqTv https://t.co/oEKTnwUvJP

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR19 abst #2476 Retrospective 2000-18 cohort study on side effects of MTX &TNFi in PSA vs RA: more side effects reported in MTX-PSA (42-46%) compared to MTX-RA pts (26-30%) or PsA or RA pts initiating a TNFi (20-25% of RA and 22-27% of PsA) @DrPetryna https://t.co/Eo3zwDgJMr https://t.co/eaq1gfD1eX

Links:

Dr. John Cush RheumNow ( View Tweet)
60%!!! - Thats the percentage of patients at @NIH's autoinflammatory disease (FEBRILE) cohort that are undifferentiated and do not have a specific disease diagnosis according to Dr. Amanda Ombrello. #ACR19 @hausmannMD

Dr. John Cush RheumNow ( View Tweet)

#ACR19 ABS# 1481 Corrona PsA/SpA Registy: real-world use of COMBINATION Apremilast + biologics happens mostly in pts who received prior biologic therapy & pts not able to achieve MDA. @DrPetryna https://t.co/7OdLBalnPZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×